|
|
|
|
The following organizations include medical, consumer, and patient advocacy groups. They offer a wealth of information for both for you and your patients.
The Web sites below are external to GlaxoSmithKline. GlaxoSmithKline does not possess editorial control over the content of the information provided in these Web sites and therefore does not warrant their accuracy or completeness.
|
1080 Montreal Avenue
St. Paul, MN 55116
800-879-1960
651-695-2791 (Fax)
www.aan.com
|
4700 W. Lake Avenue
Glenview, IL 60025
888-557-2266 (US only)
877-734-8677 (Fax)
www.aann.org
|
342 North Main Street
West Hartford, CT
06117-2507
860-586-7505
860-586-7550 (Fax)
www.aesnet.org
|
1414 Prince Street, Suite
204
Alexandria, VA 22314
703-683-9420
703-683-9431
(Fax)
www.atra-tr.org
|
1000 West Country Road
E, Suite 290
St. Paul, MN 55126
651-486-9447
651-486-9436
(Fax)
www.childneurologysociety.org
|
505 North Lake Shore Drive,
Suite #4605
Chicago, IL 60611
312-923-9117
312-923-9118
(Fax)
www.CUREepilepsy.org
|
This Web site also includes
the Women and Epilepsy Initiative.
4351 Garden City
Drive
Landover, MD 20785-7223
800-332-1000
www.epilepsyfoundation.org
|
690 Market Street, Suite 600
San Francisco, CA 94104
415-434-3388
800-445-8106
415-434-3508 (Fax)
www.caregiver.org
|
(Department of Health and Human Services Web
site)
PO Box 1133
Washington, DC 20013
www.healthfinder.gov
|
5775 Wayzata
Boulevard
Minneapolis, MN 55416
888-525-6232
952-525-1560
(Fax)
www.naecepilepsy.org
|
4915 St. Elmo
Avenue, Suite 505
Bethesda, MD
20814
301-656-8565
301-656-4464 (Fax)
www.talkaboutrx.org
|
10400 Connecticut Avenue,
#500
Kensington, MD 20895
800-896-3650
301-942-2302
(Fax)
www.nfcacares.org
|
PO Box
5801
Bethesda, MD 20824
800-352-9424
www.ninds.nih.gov
|
55 Kenosia Avenue
PO Box 1968
Danbury, CT 06813-1968
203-744-0100
800-999-6673 (voicemail only)
203-798-2291 (Fax)
www.rarediseases.org
|
11 Dupont Circle
NW, Suite 500
Washington, DC
20036
202-462-6688
202-462-9740 (Fax)
www.sfn.org
|
|
The Library offers specialized information from GlaxoSmithKline that can be useful in the treatment and management of epilepsy.
|
|
The Pregnancy Registry offers a unique opportunity for you and your female patients to contribute to the evolving knowledge base concerning LAMICTAL and pregnancy.
|
| Safety and effectiveness of LAMICTAL have not been established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate, or 3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.
|
Important Safety Information
 |
| • |
Serious rashes requiring hospitalization and discontinuation of treatment have been reported in association with the use of LAMICTAL, some of which have included Stevens-Johnson syndrome
|
| |
| - |
Epilepsy clinical trials: The incidence of these rashes is approximately 0.8% (8/1000) in pediatric patients (age <16 years) receiving LAMICTAL as adjunctive therapy and 0.3% (3/1000) in adults on adjunctive therapy. In a prospectively followed cohort of 1983 pediatric patients taking adjunctive LAMICTAL, there was 1 rash-related death
|
|
| • |
In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate
|
| • |
Hypersensitivity reactions, some fatal or life-threatening, have occurred in association with the use of LAMICTAL. It is important to note that early manifestations of hypersensitivity (eg, fever, lymphadenopathy) may be present even though a rash is not evident. If such signs or symptoms are present, the patients should be evaluated immediately. LAMICTAL should be discontinued if an alternative etiology cannot be established
|
| • |
Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (eg, fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately
|
| • |
To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations of LAMICTAL should not be exceeded
|
| • |
LAMICTAL should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug-related
|
|
Complete Prescribing Information for LAMICTAL® (lamotrigine) Tablets
For the latest medical updates on epilepsy treatment, visit the Web sites for the American Epilepsy Society, the American Academy of Neurology, and the Child Neurology Society.
|
|
 |
|
|
|
|
|
Visit news to view clinical studies about LAMICTAL.
|
|
 |
|
